MedPath

abiraterone acetate

These highlights do not include all the information needed to use ABIRATERONE ACETATE TABLETS safely and effectively. See full prescribing information for ABIRATERONE ACETATE TABLETS. ABIRATERONE ACETATE tablets, for oral use Initial U.S. Approval: 2011

Approved
Approval ID

b3e7f851-4132-4003-8f14-0eea21e5009c

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Apr 28, 2023

Manufacturers
FDA

Florida Pharmaceutical Products, LLC.

DUNS: 084014259

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

abiraterone acetate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code71921-178
Application NumberANDA212462
Product Classification
M
Marketing Category
C73584
G
Generic Name
abiraterone acetate
Product Specifications
Route of AdministrationORAL
Effective DateAugust 1, 2022
FDA Product Classification

INGREDIENTS (8)

microcrystalline celluloseInactive
Code: OP1R32D61U
Classification: IACT
abiraterone acetateActive
Quantity: 250 mg in 1 1
Code: EM5OCB9YJ6
Classification: ACTIB
lactose monohydrateInactive
Code: EWQ57Q8I5X
Classification: IACT
croscarmellose sodiumInactive
Code: M28OL1HH48
Classification: IACT
POVIDONE K30Inactive
Code: U725QWY32X
Classification: IACT
sodium lauryl sulfateInactive
Code: 368GB5141J
Classification: IACT
silicon dioxideInactive
Code: ETJ7Z6XBU4
Classification: IACT
magnesium stearateInactive
Code: 70097M6I30
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.